$2.04
+0.01 (+0.49%)
Open$2.04
Previous Close$2.03
Day High$2.09
Day Low$1.97
52W High$2.66
52W Low$0.40
Volume—
Avg Volume742.3K
Market Cap273.16M
P/E Ratio—
EPS$-1.90
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,161.3% upside
Current
$2.04
$2.04
Target
$25.73
$25.73
$15.89
$25.73 avg
$34.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.10M | 17.71M | 19.64M |
| Net Income | 3.87M | 3.06M | 4.04M |
| Profit Margin | 21.4% | 17.3% | 20.6% |
| EBITDA | 5.83M | 6.29M | 6.55M |
| Free Cash Flow | 3.85M | 4.93M | 3.44M |
| Rev Growth | +0.2% | -1.6% | +10.4% |
| Debt/Equity | 0.48 | 0.65 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |